Consortium québécois sur la découverte du médicament Facilitating creative partnerships in biopharmaceutical research OTTAWA - December 1 st, 2009 Max

Consortium québécois sur la découverte du médicament

Facilitating creative partnerships in biopharmaceutical research

OTTAWA - December 1st, 2009

Max Fehlmann, President & CEO

Panel Discussion : Open Innovation


Industry R&D Productivity is Decreasing


The BIG Picture


The Pharmas Patent Expirations 2007-2012


$ 67 BILLION

The Pharmas Patent Expirations 2007-2012


Rethinking the Pharma R&D Business Model : Open Innovation


Rethinking the Pharma R&D Business Model : Open Innovation


Pre-competitive Pharma research consortia





http://www.imi-europe.org/










Our Mission


Our Mission

To create a collaborative ground between the academic and private sectors based on trust, creativity and mutual benefit


To create a collaborative ground between the academic and private sectors based on trust, creativity and mutual benefit

To identify, finance and support innovative research activities, primarily focusing on enabling technologies in drug discovery, fulfilling the innovation needs of the pharmaceutical industry

Our Mission


Areas of Activities


A fully mutualized consortium


Benefits to Canada

Benefits to Pharma companiesAccess to innovation

Closer links with the academic andBiotech sectors

Excellent leverage (>10 fold) for R&D investment

Closer interactions with government bodies

Benefits to Biotechs and Academic

institutionsAdditional source of funding

Closer links with industrial colleagues

Documents

Consortium québécois sur la découverte du médicament Facilitating creative partnerships in biopharmaceutical research OTTAWA - December 1 st, 2009 Max